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CHAPTER 1 
INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, 
ibuprofen, and naproxen, are widely used to reduce pain, fever, and headaches 
associated with inflammation. The therapeutic benefits of these drugs are 
associated with the inhibition of cyclooxygenases 1 and 2 (COX-1 and COX-2). 
Of the two forms, COX-1 is the constitutively active isoform and is responsible for 
converting arachidonic acid into prostaglandins that are generally accepted to be 
“house-keeping” prostaglandins. COX-2 is the inducible part of the pathway that 
is responsible for converting arachidonic acid into inflammatory prostaglandins 
that result in pain, swelling, redness, and other inflammatory responses. 
Traditional NSAIDs non-specifically inhibit COX-1 and COX-2, meaning they 
inhibit both the inflammatory and house-keeping sides of the COX pathway. The 
non-specific nature of NSAIDs results in adverse effects that come about as a 
consequence of inhibiting the COX-1 pathway. The most noted adverse effects of 
COX-1 inhibition are gastric complications that result from the disruption of 
prostaglandin E2 production [1]. These gastric complications resulted in a 
population of patients who could not tolerate traditional NSAID use. These 
patients needed an alternative medication that could offer the anti-inflammatory 
properties of NSAIDs without the gastric complications.  
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Coxibs were developed to meet the need of patients who could not 
tolerate traditional NSAID use. Coxibs specifically inhibit the inflammatory COX-2 
pathway while leaving the COX-1 pathway relatively unaffected. This was meant 
to give patients the anti-inflammatory benefits of blocking the COX-2 pathway 
without the gastric complications associated with traditional NSAID use. The 
coxibs originally developed were celecoxib (Celebrex®), rofecoxib (Vioxx®), 
valdecoxib, etoricoxib, and lumiracoxib. The coxibs were available on the market 
just 5 years after animal model validation in 1994, making it one of the most rapid 
drug discovery and development efforts [2]. The need for these drugs was 
validated when celecoxib and rofecoxib garnered a combined sales total of 
almost 2 billion dollars in their first years on the market [2]. This initial success 
lead to an aggressive advertising campaign for both drugs. The advertising 
exposed many more people to a class of drugs that was originally developed for 
patients who could not tolerate traditional NSAIDs. This upsurge in popularity of 
coxibs lead to the launch of clinical trials that would add to the labeled uses of 
these drugs. One of these clinical trials was the Adenomatous Polyp Prevention 
on Vioxx (APPROVE) [2].  During this and two parallel trials, patients on 
rofecoxib were found to have an almost 2-fold increase in the occurrence of 
cardiovascular side effects; these side effects included myocardial infarctions 
and ischemic cerebrovascular events [3-5].  These findings caused Merck to 
withdraw Vioxx from the market within days of the report being released. The 
following year, valdecoxib was withdrawn from the market for similar reasons [2]. 
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The negative publicity associated with the withdrawal of rofecoxib and valdecoxib 
from the market led to a push to determine the cardiovascular risk profiles of 
celecoxib (Celebrex®) and other coxibs still on the market.  
 A review of randomized clinical trials of COX inhibitors revealed that 
rofecoxib and diclofenac both significantly increased the risk of cardiovascular 
events [3], but a number of clinical trials were unable to establish the same 
increased cardiovascular risk with celecoxib [3, 6]. The mechanism behind this 
difference in cardiovascular risk is still unknown and the exact reason behind this 
difference is widely debated. Several studies reported celecoxib to exhibit 
vasorelaxant effects [7, 8] which may account for its differential risk profile 
compared to other COX-2 inhibitors. Our laboratory attempted to explore the 
mechanisms behind the vasodilatory actions and lower CV risk for celecoxib by 
examining the effects of celecoxib and other NSAIDs on vascular smooth muscle 
ion channels. Brueggemann et al. focused their attention on two types of ion 
channels that are important in determining the contractile state of vascular 
smooth muscle cells (VSMCs): KCNQ (Kv7 family) potassium channels that 
determine the resting membrane voltage and L-type voltage gated calcium 
channels, the activation of which induces calcium ion influx, smooth muscle 
contraction, and vasoconstriction [9]. In that study, our laboratory provided 
evidence that celecoxib, but not rofecoxib or diclofenac, activated Kv7 potassium 
channels and inhibited L-type calcium channels at comparable therapeutic 
concentrations, promoting vasorelaxation and decreasing vascular tone. 
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Celecoxib’s ability to modulate these ion channels was also found to be 
independent of its COX-2 inhibitory effects. A celecoxib analog, 2,5-
dimethylcelecoxib (DMC) which does not inhibit COX-2, mimicked both 
celecoxib’s activation of Kv7 channels and inhibition of L-type channels [9]. That 
study ultimately led to the hypothesis that the COX-2 independent ion channel 
modulatory actions of celecoxib may account for the reduced cardiovascular risk 
in patients taking celecoxib compared to other coxibs.  
The mechanism that underlies celecoxib’s ion channel modulatory actions 
is still not known. As stated previously, it is believed that these actions are 
independent of celecoxib’s COX-2 inhibitory activity [9]. Given the differential ion 
channel modulatory activities reported for celecoxib and rofecoxib, it stands to 
reason that the mechanism by which celecoxib activates Kv7 potassium 
channels would be stimulated by celecoxib and not by rofecoxib. One such 
mechanism is cyclic nucleotide phosphodiesterase (PDE) inhibition. Klein et al. 
reported that celecoxib and not rofecoxib, inhibited the PDE4 isoform, which 
specifically degrades cyclic adenosine monophosphate (cAMP) [8]. cAMP-
specific cyclic nucleotide PDE inhibition results in higher cellular levels of cAMP 
which goes on to affect many downstream targets. One well known target of 
cAMP is protein kinase A (PKA). Activation of PKA by cAMP leads to the 
phosphorylation and activation of many downstream targets, one of which may 
be Kv7 potassium channels. In this thesis, I hypothesize that activation of the 
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cAMP/PKA pathway is necessary and sufficient to induce the activation of Kv7 
potassium channels in vascular smooth muscle cells. 
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CHAPTER 2 
REVIEW OF RELEVANT LITERATURE 
KCNQ Channels 
Discovery 
 Kv7 potassium channel subunits are encoded by five genes (KCNQ1-5) 
that were first cloned in the 1990s.  The Kv7 nomenclature given to this family of 
channels was based on the deducted phylogenetic relationships [10] and is used 
interchangeably with KCNQ based on the Human Genome Organization’s KCN 
nomenclature [11]. 
 KCNQ1 was the first of the Kv7 channels to be discovered. It was 
originally named KvLQT1 because it was discovered in the heart and was found 
to co-assemble with MinK (which is encoded by the KCNE gene) to form slowly 
activating delayed-rectifier K+ channels (IKs) whose dysfunction results in long-
QT syndrome which can result in fatal cardiac arrhythmias. IKs currents 
modulate repolarization of cardiac action potentials [12]. 
M-currents in the brain are responsible for regulating the subthreshold 
excitability of neurons. KCNQ2 and KCNQ3’s properties were determined and it 
was reported that the hetero-tetramerization of those two channel subunits is 
what underlies neuronal M-current. This conclusion was reached because of their 
kinetic properties, which were similar to previously recorded native M-currents, 
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and their sensitivity to muscarinic inhibition (where the M in M-current is derived) 
[13]. 
To date, KCNQ1-5 (which encode Kv7.1-7.5 channel subunits 
respectively) have all been cloned and the channels formed by these subunits 
have important functions in many types of excitable tissues [14]. 
  
Structure and composition of functional channels 
The functional Kv7 channels resemble other Kv channels in that they are 
composed of homo- or hetero-tetramers of six transmembrane spanning (S1-S6) 
subunits [14]. The P-loop (single pore loop) formed between the S5 and S6 
domains form the selectivity filter of the pore. The S4 domain consists of 
positively charged arginine residues and acts as a voltage sensor. Both the N- 
and C-terminus of the channel are present on the cytoplasmic side of the 
membrane. A distinct feature of Kv7 channels is that they have a long 
intracellular C-terminus [15]. The C-terminus contains a distinctive A-domain that 
determines the subunit specificity of the channels [16]. This distinctive C-
terminus is important for channel gating, assembly, and trafficking [17].  
The five channel subunits can assemble in a number of conformations. 
First, each channel is able to form a homo-tetramer which consists of four of the 
same alpha subunits. These channel subunits can also form hetero-tetramers, 
but the subunit combinations are limited. Kv7.1 is unable to form a hetero-
tetramer with any of the other Kv7 channel subunits, but it has been suggested 
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that it co-assembles with KCNE1 which encodes the ancillary protein MinK [18]. 
Kv7.2 and Kv7.3 form a hetero-tetramer that underlies the M-current of the brain 
[13]. Kv7.4 can form a hetero-tetramer with Kv7.3 but not Kv7.2 or Kv7.1 [19, 20]. 
Kv7.5 can form a hetero-tetramer with Kv7.3 and Kv7.4 but not Kv7.2 [21, 22].  
To date, there is no evidence of Kv7 channel subunits assembling with 
any other Kv channel subunits (such as Kv1, Kv2, or Kv4).  
 
Expression 
Originally, Kv7 channels were thought to be expressed only in neurons 
and cardiac myocytes, however, more recent evidence suggests a ubiquitous 
expression profile [23, 24]. Additionally, channel expression and assembly varies 
by tissue.  
In the heart, Kv7.1 channel subunits form homo-tetramers that conduct the 
cardiac delayed rectifier current, IKs. This current is responsible for modulating 
cardiac repolarization. These Kv7.1 channels have been reported to co-assemble 
with MinK which is a single transmembrane spanning auxiliary β-subunit encoded 
by the KCNE1 gene. Assembly of MinK with KV7.1 channel subunits leads to 
slowing of Kv7.1 activation, an increase in unitary conductance, removal of 
inactivation, and an altered regulation and pharmacology of the complex [18]. 
Mutations in either KCNQ1 or KCNE1 genes can result in long QT syndrome 
(LQTS).  
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A study by Oliveras et al. suggested the formation of functional 
heteromeric complexes between Kv7.5 and Kv7.1 channels (possibly with 
KCNE1 and/or KCNE3 regulatory subunits) within the vasculature. This 
conclusion was based on the ability of Kv7.1, Kv7.5 and KCNE1 to co-
immunoprecipitate in rat aorta myocytes. They also observed Kv7.1 and Kv7.5 
forming functional channels with distinct biophysical and pharmacological 
properties in an expression system [25]. However, the functionality of Kv7.1 
channels in arterial myocytes as homotetramers or in a heteromeric complex with 
Kv7.5 subunits requires further exploration. 
Expression of KCNQ genes in smooth muscle will be discussed later in 
this chapter. 
 
Biophysical properties 
 Outward potassium currents that are conducted through Kv7 channels 
have unique biophysical characteristics. First, the threshold of activation is 
approximately the same as the resting membrane voltage, usually around                
-60mV. Second, when the membrane depolarizes from resting voltages, there is 
a slow, voltage-dependent enhancement of the currents through the channels. 
Third, the currents do not inactivate [26, 27]. These biophysical characteristics 
suggest activation of Kv7 channels would oppose membrane depolarization and 
decrease the excitability of excitable cells. Therefore, inhibition of these channels 
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increases the likelihood of action potential firing, L-type calcium channel 
activation, calcium influx, and smooth muscle contraction. 
Regulation 
PIP2 Mediated 
Phosphatidylinositol-4,5- bisphosphate (PIP2) plays a central role in the 
regulation of many voltage-sensitive potassium (Kv) channels. The Kv7 family of 
potassium channels is unique in that it has been reported to require PIP2 in order 
to conduct current [28]. The best characterized of these interactions involve M-
current KCNQ2/KCNQ3 in expression systems [29]. Agonists of Gq/11-coupled 
receptors cause M-current suppression and increase neuronal excitability. This 
suppression can be attenuated by phospholipase C (PLC) inhibitors and recovery 
from this suppression requires ATP [30]. Zhang and colleagues reported 
evidence that PIP2 was required for activation of KCNQ channels. They reported 
application of PIP2 to inside-out macropatches rescued both homomeric Kv7.2 
and heteromeric Kv7.2/7.3 channel activities. Additionally, they tested the PIP2 
sensitivity of Kv7.1, Kv7.1/KCNE1, Kv7.4, and Kv7.5 and found that all of these 
family members were sensitive to PIP2 since bath application of PIP2 rescued the 
channel activities of all of these subtypes [31]. It has been suggested that this 
increase in activation of Kv7 channels by PIP2 is the result of a PIP2-mediated 
increase in the open probability of the channels. Li and colleagues reported that 
each channel is differentially sensitive to PIP2 and this sensitivity is paralleled in 
the differential increase in open probability of each channel subtype [32]. 
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Signaling Complexes 
 Signaling complexes have been implicated in regulating the specificity and 
efficiency of signal transduction pathways [33]. Signaling complexes mediate 
specificity of signaling pathways by bringing specific signaling molecules into the 
proximity of specific substrates, thereby compartmentalizing signaling events. 
There have been reports that Kv7 channels are involved in signaling complexes 
brought together by the scaffolding protein A-kinase anchoring protein (AKAP) 
79/150 in neurons. AKAP79/150 is a family of 3 orthologs: human AKAP79, 
murine AKAP150, and bovine AKAP75 [34]. As its name suggests, AKAP is able 
to bind protein kinase A (PKA). It is also reported to bind to protein kinase C [35], 
phosphodiesterases [36], and Kv7 channels [15]. AKAP was reported to interact 
with Kv7.2-7.5 channels but not Kv7.1 using fluorescence resonance energy 
transfer (FRET) under total internal reflection fluorescence (TIRF) microscopy 
[22]. 
Phosphorylation 
 Phosphorylation of Kv7 channels by the non-receptor tyrosine kinase, Src, 
was reported to inhibit currents by reducing the open probability of the channels. 
Src phosphorylation is selective for Kv7.2, Kv7.3, Kv7.2/7.3, and Kv7.5 channel 
subunits [37]. The specific tyrosines phosphorylated by Src on the Kv7.3 subunit 
were reported to be Y67 on the N-terminus and Y349 on the C-terminus. 
Simultaneous phosphorylation of these two residues was reported to be required 
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for Src regulation of the channel [38]. The physiological significance of Kv7 
channel regulation by Src phosphorylation is unknown. 
Transcriptional 
Rose and colleagues reported transcriptional regulation of KCNQ2 in dorsal root 
ganglia neurons by repressor element 1-silencing transcription factor (REST) 
[39]. They reported that an upregulation of REST in situations such as 
neuropathic pain and injury (typified by an overexcitability of the neurons) leads 
to a downregulation of KCNQ2. This gene encodes for the Kv7.2 channel 
subtype that, together with Kv7.3, form functional channels that underlie the M 
current of the brain and control neuronal excitability. They showed that 
application of the Kv7 channel activator, flupirtine, was able to alleviate the 
neuropathic hyperalgesia in their rat model, further highlighting the importance of 
Kv7 channels in neuronal excitability [39]. 
Pharmacology of KCNQ channels 
 Pharmacological agents have been developed that modulate Kv7 channel 
activity. Linopirdine [DuP, 1, 3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-
2Hindol-2-one] is a derivative of phenylindolinone and was developed to be a 
cognitive enhancer [40]. It and its more potent analog, XE991 are effective 
blockers of all five subtypes of Kv7 channels. Activators of the Kv7 channels 
have been developed as well. Flupirtine [D-9998, Katadolon®, ethyl 2-amino-6-
((p-fluorobenzyl)amino)-3-pyridinecarbamate] is a triaminopyridine and is used 
clinically as non-opioid analgesic in Europe. Modification of flupirtine’s structure 
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yielded the antiepileptic drug, retigabine [also known as ezogabine in the United 
States; D-23129, ethyl N-[2-amino-4-[(4-fluorophenyl) methylamino) 
phenyl)carbamate].  Retigabine was reported to augment GABA-ergic signal 
transduction in the central nervous system, however, it was reported to be a 
much better activator of potassium channels at therapeutic ranges [41]. Both 
retigabine and flupirtine activate Kv7 potassium channels Kv7.2-7.5 through 
interaction with residues in the S5 and S6 pore forming domains. Kv7.1 is the 
only Kv7 channel subtype that is insensitive to regulation by these Kv7 channel 
activators. There exists a tryptophan residue in the S5 domain of subtypes 
Kv7.2-7.5 that is critical for channel activation that Kv7.1 subunits lack that 
render them unaffected by these typical pharmacological Kv7 channel activators 
[42]. 
Kv7 channel activators like retigabine do not distinguish amongst the Kv7 
channel subunits and can give rise to possible off-target effects when activating 
potassium channels in tissues outside of the central nervous system. In recent 
years, drugs have been developed to specifically target certain Kv7 channel 
subunits over others. ICA-27243 (N-(6-chloro-pyridin-3-yl)-3, 4-difluoro-
benzamide) was found to be a 20-fold more potent activator of Kv7.2/7.3 
heteromeric channels than of homomeric Kv7.4 channels. It was reported to have 
no effect on Kv7.3 homomeric channels and only elicit weak activation of 
Kv7.3/7.5 heteromeric channels.  
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 The only drug reported to distinguish between Kv7.4 and Kv7.5 channel 
was diclofenac, an NSAID with an affinity for COX-2 similar to that of celecoxib. 
Diclofenac enhanced Kv7.4 channel currents, suppressed Kv7.5 channels 
currents, and produced an intermediate effect on Kv7.4/7.5 heteromeric channel 
currents expressed in A7r5 cells [43]. ML213 (N-mesitybicyclo[2.2.1]heptane-2-
carboxamide) was a newer clinically available drug that claimed to be a selective 
activator of Kv7.2 and Kv7.4. Brueggemann et al. conducted a rigorous 
electrophysiological exploration of this claim by testing ML213’s effect on hKv7.4, 
hKv7.5, and hKv7.4/7.5 channel currents exogenously expressed in A7r5 cells. In 
contrast to what was previously reported [44], Brueggemann et al found that 
ML213 robustly enhanced the currents of all three channel assemblies with no 
apparent specificity. Additionally, they tested ICA-069673 (N-(6-chloropyridin-3-
yl)-3,4-difluorobenzamide) and found that it more effectively enhanced Kv7.4 
channel currents compared to Kv7.5 channel currents but in a comparable 
manner to Kv7.4/7.5 heteromeric channel currents [45]. Finding pharmacological 
agents that can distinguish between the different Kv7 channel subunits is still an 
important endeavor that needs to be explored further. 
Channels as therapeutic targets 
 It is becoming increasingly clear that Kv7 modulation can be utilized as a 
therapeutic target for a variety of diseases. In particular, pharmaceutical agents 
can be developed to relieve ailments that involve overexcitability of the cells such 
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as anxiety [46]  and neuropathic pain [39], since activation of these Kv7 channels 
decreases the excitability of the cells by promoting membrane hyperpolarization.   
Channels in vascular smooth muscle cells 
 Ohya and colleagues were the first to report the existence of Kv7 channels 
in vascular smooth muscle cells when they reported the expression of KCNQ1 
transcripts in murine portal vein myocytes [47]. This same group then published a 
follow up study where Kv7 channel blockers, linopirdine and XE991 were applied 
to the portal vein and induced membrane depolarization and increased 
spontaneous contractile responses [48]. These studies demonstrated the 
importance of Kv7 channels and their contribution to vascular smooth muscle 
membrane voltage. 
 Another important finding for Kv7 channels in vascular smooth muscle 
cells was reported by Brueggemann et al. who isolated Kv7 currents in cultured 
rat embryonic aortic smooth muscle cells (A7r5 cells). They also reported 
KCNQ5 mRNA expression in both A7r5 cells as well as rat aortic smooth muscle 
cells. KCNQ1 mRNA transcripts were only expressed in rat aortic smooth muscle 
cells and were not expressed in A7r5 cells [49].  
 There have been several studies since Brueggemann et al. that 
demonstrated KCNQ expression in different vascular beds such as mesenteric, 
pulmonary, carotid, cerebral, aorta, and femoral artery. The general consensus of 
KCNQ expression shown by these studies is KCNQ1, KCNQ4, and KCNQ5 
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mRNA transcripts predominating with little to no expression of KCNQ2 or KCNQ3 
[50-53].  
 The expression and function of Kv7 channels reported in human arteries 
were found to be similar to rodent models, thus validating the role of Kv7 
channels in regulating vasoconstriction and vascular tone in humans [54]. Kv7.1 
channels were originally thought to only be expressed in the heart but have been 
found in all human and rat myocytes studied to date. However, it is unlikely that 
channels formed by Kv7.1 channel subunits contribute significantly to vascular 
tone. This conclusion is based on the ability of Kv7.2-5 activator, retigabine, to 
dilate pre-constricted human or rat arteries and the inability of the Kv7.1-specific 
channel blocker, chromanol 293B to constrict human or rat arteries [50, 52-54]. 
While channels formed by Kv7.1 subunits do not contribute to resting vascular 
tone, Chadha et al. reported that selective activation of Kv7.1 channels dilated 
pre-constricted arteries and suggested that these channels may function under 
certain conditions in VSMCs [55]. 
While more is being discerned about the expression and function of Kv7 
channels in the vasculature, there is still much that is unknown about any 
changes in expression of KCNQ during development. There has been a report, 
however, that the KCNQ4 gene was downregulated in the aorta of a rat model of 
hypertension which correlated to a decrease in Kv7.4 channel protein [56]. This 
downregulation was not observed in the same rat model within the skeletal or left 
coronary arteries [57, 58]. Mesenteric artery expression proved to be even more 
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inconsistent. Zavaritskaya and colleagues reported a reduction in levels of Kv7.4 
channels within mesenteric arteries of spontaneously hypertensive rats (SHR) 
relative to the same arteries from normotensive Wistar rats, but Khanamari and 
colleagues did not detect any changes in KCNQ gene expression between 
hypertensive and normal rats [57, 58]. Despite the lack of change detected in 
mRNA levels, a reduction of Kv7.4 channel protein was reported in mesenteric 
arteries of hypertensive rats [56, 57]. A reduction in Kv7.4 channel proteins has 
also been reported in renal arteries of hypertensive rats [59]. In contrast to the 
multiple reports of Kv7.4 expression changes in hypertensive animal models, 
there is not a lot known about Kv7.5 expression in hypertension. Initial reports by 
Jepps and colleagues showed an increase in KCNQ5 gene expression in 
hypertension but later reports by this same group showed an insignificant 
reduction of KCNQ5 gene expression. The protein levels of Kv7.5 were not 
examined in either report [56, 57]. 
The Kv7 currents isolated from A7r5 cells and mesenteric artery myocytes 
were outwardly rectifying and showed a threshold of activation around -60mV 
[49, 53]. Kv7 channels activate at resting membrane voltages which is more 
negative than the threshold of activation of voltage-sensitive calcium channels 
(VSCCs; ~ -40mV) and promote membrane hyperpolarization which opposes 
activation of VSCCs in vascular smooth muscle cells. Kv7.5 monomeric channels 
are the only subtype of Kv7 channel expressed in A7r5 cells [43] and knockdown 
of these channels via KCNQ5 short hairpin(sh)-RNA resulted in membrane 
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depolarization which in turn, induced repetitive spontaneous Ca2+ spiking [60]. 
The Ca2+ spiking response was dependent on membrane depolarization and 
activation of VSCCs [61]. Therefore, Kv7 channels regulate the contractile status 
of VSMCs by regulation of membrane voltage which determines activation of 
VSCCs. 
Kv7 channel suppression has been suggested to be the mechanism 
through which the hormone arginine vasopressin elicits its vasoconstrictor effects 
[49, 53]. This reported suppression was dependent on the activation of protein 
kinase C which is a common signaling intermediate in the Gq/11-coupled receptor 
signaling pathway [49, 53]. In contrast, activation of protein kinase A has been 
shown to enhance the activity of certain Kv7 channel subtypes in expression 
systems [62, 63]. PKA activation is a known consequence of Gs-coupled receptor 
signaling. The β-adrenergic receptor is one such Gs-coupled receptor whose 
activation could potentially lead to vasodilation in VSMCs by regulation of Kv7 
channels.  
Phosphodiesterases 
Signaling 
Cyclic nucleotide concentrations within the cell are determined by the 
balance between their synthesis (which is catalyzed by cyclases) and their 
degradation (which is catalyzed by phosphodiesterases (PDEs)). When a 
stimulatory (GαS) G-protein coupled receptor (GPCR) is activated, it goes on to 
activate adenylyl cyclase, which is responsible for synthesizing cyclic adenosine 
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monophosphate (cAMP). Certain PDEs degrade cAMP and thereby attenuate 
cAMP-dependent cell signaling [64]. Inhibition of cAMP-specific PDEs results in 
an attenuation of cAMP degradation thereby increasing the overall cellular cAMP 
concentration. This increase in cAMP concentration leads to enhanced 
downstream signaling of many cAMP effectors, the best characterized of which is 
protein kinase A (PKA) [65]. PKA is a symmetrical complex containing two 
regulatory and two catalytic subunits. Activation occurs when cAMP binds to sites 
on the regulatory subunits, causing a dissociation from the catalytic subunits [66]. 
PKA is a serine/threonine kinase that, once activated, goes on to phosphorylate 
its own downstream targets. One such target of PKA could be the Kv7 potassium 
channels of interest in this thesis. This question will be addressed by later 
experiments. 
Characteristics 
 There are 11 members of the PDE family encoded by different genes [64]. 
Each member is able to specifically degrade cAMP, cyclic guanosine 
monophosphate (cGMP), or both. The cAMP-specific isoforms of PDE in 
mammals are PDE4, PDE7, and PDE8. PDE5, PDE6, and PDE9 hydrolyze 
cGMP specifically, and the 5 remaining PDEs (PDE1, 2, 3, 10, and 11) can 
hydrolyze both cAMP and cGMP [67]. This substrate specificity has been 
suggested to be due to a glutamine residue within the catalytic site. This residue 
can form hydrogen bonds with cAMP, cGMP, or both depending on its orientation 
within the catalytic site and its ability to rotate [68]. Each PDE subtype has 
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multiple isoforms and splice variants, which increases the difficulty in pinpointing 
particular isoforms as essential contributors to specific pathological conditions 
[64].   
PDE4 
 The PDE4 family selectively hydrolyzes cAMP and is encoded by four 
genes: PDE4A, PDE4B, PDE4C, and PDE4D. These genes have different 
promoters which give rise to a multitude of proteins via splice variants [64]. More 
than 25 human isoforms have been identified, and PDE4 is found in several 
tissues including brain, lung, testis, and immune cells [67]. These PDE4 variants 
are localized within tissues by protein kinase A anchoring proteins (AKAPs) [69, 
70] near PKA to regulate cAMP signaling and functional responses [36]. PDE4 
has been targeted in recent years for inflammatory conditions such as asthma 
and chronic obstructive pulmonary disease (COPD). This exploration was based 
on the findings that elevating cAMP levels within inflammatory cells inhibited their 
function and that PDE4 was widely distributed within inflammatory cells and the 
lung [71, 72]. Therefore, the first PDE4 inhibitors were developed to effectively 
inhibit a wide range of inflammatory cell functions. This anti-inflammatory action 
coupled with the ability to induce relaxation in isolated human bronchus [73] 
showed promise for PDE4 inhibitors as an effective treatment for patients 
suffering from asthma and COPD. 
 Klein and colleagues reported celecoxib, and not rofecoxib, to be a 
specific inhibitor of PDE4 and PDE5. The evidence presented in that study was 
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more strongly suggested that celecoxib was a cGMP-specific PDE5 inhibitor than 
a cAMP-specific PDE4 inhibitor [8]. The evidence for PDE5 inhibition by this 
group included celecoxib’s ability to increase coronary flow in a guinea pig 
Langendorff heart, celecoxib’s ability to relax rat aortic ring preparations that 
were pre-constricted with phenylephrine, an increase in cGMP levels in aortic 
ring tissue in response to celecoxib treatment (as measured by an 
immunoassay), and an in vitro measurement of PDE5A1 inhibition using a 
recombinant human enzyme [8]. The evidence for PDE4 inhibition was not as 
strong. Klein and colleagues reported that celecoxib increased cAMP levels in rat 
aortic tissue 1.6-fold but that it never reached statistical significance and the data 
was not shown [8]. They also reported celecoxib inhibited a recombinant human 
PDE4 enzyme, but again, the data was not shown [8]. 
Hypertension 
Hypertension is the leading risk factor for cardiovascular disease and is a 
major cause of mortality [74]. About 1 in 3 American adults have high blood 
pressure and only about half of all adults suffering from high blood pressure have 
it under control [74]. Hypertension is characterized by chronic elevation in blood 
pressure and can be classified into two categories. Primary or essential 
hypertension is a chronically elevated blood pressure with no identifiable cause 
while secondary hypertension is a chronically elevated blood pressure that can 
be attributed to a specific cause, such as kidney disease.  
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Blood pressure is directly proportional to the product of the blood flow 
(cardiac output, CO) and the resistance of blood passage through precapillary 
arterioles (peripheral vascular resistance, PVR) [75].   
Hypertension, in general, has been associated with increased vascular 
tone that results from a more depolarized membrane potential in VSMCs. This 
evidence makes it clear that understanding the role of the potassium channels 
that regulate VSMC membrane potential is important. To that end, there have 
been reports that certain Kv7 potassium channels are downregulated in 
hypertension. The Greenwood lab reported that of the 5 KCNQ genes, only 
KCNQ4 was downregulated in hypertensive rats [59]. Since Kv7.4 and Kv7.5 
subunits form both homo- and hetero-tetramers in the vasculature, it is possible 
that the selective downregulation of KCNQ4 could lead to increased formation of 
Kv7.5 homotetramers in these patients. This means drugs like celecoxib, which 
activate Kv7.5 potassium channels, could prove to be therapeutically beneficial in 
patients suffering from this type of hypertension. 
Current Treatments 
 The currently used treatments for hypertension can be categorized into 
four main categories: diuretics, sympathoplegic agents, direct vasodilators, and 
agents that block the production/action of angiotensin. Diuretics lower blood 
pressure by depleting the body of sodium and lowering blood volume. 
Sympathoplegic agents reduce peripheral vascular resistance (PVR), inhibit 
cardiac function, and increase venous pooling in capacitance vessels. The latter 
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two actions effectively decreases cardiac output. Direct vasodilators are true to 
their name and decrease blood pressure by relaxing VSMCs which causes 
vasodilation in resistance vessels and could potentially increase capacitance. 
Agents that block the production and/or action of angiotensin decreases PVR to 
decrease blood pressure [75].  
 The fact that direct vasodilators are already used clinically to treat 
hypertension is promising for pharmaceutical agents such as celecoxib whose 
ability to activate Kv7 potassium channels directly opposes cell excitability and 
results in relaxation in VSMCs. Previous research from our laboratory has 
demonstrated that celecoxib can dilate mesenteric resistance arteries from rats in 
vitro and in vivo [76].
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CHAPTER 3 
RESEARCH AIMS 
In this proposal, I hypothesize that activation of the cAMP/PKA pathway is 
necessary and sufficient to induce the activation of Kv7 potassium channels in 
vascular smooth muscle cells. [Figure 1] To test this hypothesis I propose the 
following aims: 
Aim 1: Determine if PDE inhibition is sufficient to induce the 
activation of Kv7 potassium channels in vascular smooth muscle 
cells. 
 
In this aim, I will utilize PDE inhibitors that are structurally different and have 
different specificities for cAMP. The PDE4 (cAMP)-specific inhibitor, rolipram will 
be used as a comparison to celecoxib’s effects because a previous doctoral 
student, Bharath Mani, found that rolipram was able to mimic celecoxib’s ion 
channel modulatory activity in the A7r5 cell line as well as its vasorelaxant effects 
in pre-constricted vessels. I will also utilize the non-specific PDE inhibitor, 3-
isobutyl-1-methylxanthine (IBMX), in conjunction with the adenylyl cyclase 
activator, forskolin, to maximally elevate cAMP levels to determine whether or not 
maximal elevation of cAMP concentration is sufficient to mimic celecoxib’s Kv7 
channel activation. The electrophysiology experiments will utilize cells 
exogenously expressing human Kv7.4, Kv7.5 or Kv7.4/7.5 channels, since these 
are the predominant channel assemblies found in the vasculature. The results of 
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these experiments, combined with preliminary data collected from other 
members of the Byron laboratory, will give a clearer answer as to whether or not 
PDE inhibition is sufficient to induce Kv7 channel activation. 
 
Aim 2: Determine whether celecoxib-induced enhancement of Kv7.5 
currents is a consequence of a critical tryptophan residue on the 
channel. 
 
Celecoxib’s ability to activate Kv7.5 potassium channels in vascular smooth 
muscle cells could be the result of our proposed indirect mechanism or it could 
be the result of a critical tryptophan residue on the channel. Many 
pharmacological Kv7 potassium channel activators act by binding directly to the 
channel. For example, retigabine, the prototypical pharmacological Kv7 channel 
activator, binds to a homologous site on Kv7.2, Kv7.3, Kv7.4, and Kv7.5 
channels. Celecoxib was previously proposed to enhance Kv7.2 currents by 
binding to the retigabine binding region, based on the loss of this effect in a 
retigabine-insensitive mutant of Kv7.2, though this was not tested for Kv7.5 [77]. 
The retigabine binding site on Kv7.5 contains a critical tryptophan at position 235 
(W235) [42]. Kv7 channel activators like retigabine bind this tryptophan residue 
located in the S5 domain and stabilize the channel in an open position, allowing 
increased efflux of potassium ions and membrane hyperpolarization [78]. Our 
laboratory has a KCNQ5 construct that is mutated at the critical tryptophan 
residue (Q5W235L), making it retigabine-insensitive [42]. If celecoxib is working 
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through an indirect pathway (e.g. PDE4 inhibition or cAMP elevation) to activate 
Kv7 potassium channels, then celecoxib is expected to enhance the currents of 
our Q5W235L mutant. If celecoxib utilizes the retigabine binding motif on the Kv7 
channels to activate them, then application of celecoxib is not expected to 
enhance Q5W235L currents. 
Aim 3: Determine if celecoxib-induced activation of Kv7 potassium 
channels is a consequence of cAMP/PKA-dependent regulation in 
vascular smooth muscle cells.  
 
It has yet to be determined whether activation of the cAMP/PKA-dependent 
pathway is necessary for celecoxib to induce Kv7 potassium channel activation. 
There are inhibitors and dominant-negative analogs of the pathway’s 
components that can be utilized to disrupt normal signal transduction to 
determine the involvement of this pathway. Disrupting normal cAMP/PKA-
dependent signaling and observing the effect on celecoxib’s ability to activate 
Kv7 potassium channels could aid in fully elucidating celecoxib’s mechanism of 
channel activation. The inhibitor that will be utilized in this thesis work is 
(9R,10S,12S)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-
1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic 
acid, hexyl ester (KT5720). It is a PKA inhibitor that, when used as a 
pretreatment, can prevent PKA activation by cAMP [79]. If celecoxib is activating 
Kv7 channels through a cAMP/PKA dependent pathway, pretreatment with 
KT5720 should attenuate the celecoxib-induced enhancement of the Kv7 
currents. Additionally, using commercially available kits to determine whether or 
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not celecoxib is elevating cAMP levels, as we predict, will further verify 
celecoxib’s role as a PDE4 inhibitor as well as provide further evidence to help 
determine whether Kv7 channel activation by celecoxib is the consequence of 
this cAMP/PKA-dependent indirect signaling mechanism. The kit that will be 
utilized in this thesis work is the direct cAMP ELISA by Enzo Life Sciences. More 
details on this kit and the protocol used can be found in the next chapter. 
Summary of Specific Aims: 
Upon completion of the proposed research, the signaling mechanism 
involved in celecoxib’s ability to activate Kv7 potassium channels will be better 
elucidated. This will shed light on the potential differential regulation of the 
different Kv7 channel subunits in the vasculature. This could lead to the 
repurposing of already available drugs, like rolipram, to promote vasorelaxation. 
This would also give an alternative signaling pathway to target when developing 
new drugs for the purpose of promoting vasorelaxation in the vasculature. Of 
course this thesis work would not be the end to the question of Kv7 channels’ 
sensitivity to a cAMP/PKA-dependent pathway and would, instead, act as the 
starting point for a host of new scientific questions which are discussed in much 
greater detail in the discussion/future directions portion of this thesis.  
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Figure 1: Schematic of potential PDE involvement in Kv7 potassium channel 
activation and L-type Ca2+ inhibition. 
When a stimulatory (GαS) G-protein coupled receptor (GPCR) is activated, it goes 
on to activate adenylyl cyclase (AC), which is responsible for synthesizing cyclic 
adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). 
Phosphodiesterase 4(PDE4) degrades cAMP to adenosine monophosphate 
(AMP) and thereby attenuates cAMP-dependent cell signaling. Inhibition of 
cAMP-specific PDE4 by celecoxib results in an increase in cellular cAMP 
concentration. This can lead to enhanced downstream signaling of many cAMP 
effectors, one of which is protein kinase A (PKA). PKA goes on to phosphorylate 
downstream targets, one of which may be Kv7 potassium channels. Activation of 
Kv7 channels directly opposes the activation of voltage sensitive calcium 
channels (VSCC). Both Kv7 channel activation and VSCC inhibition promote 
relaxation in vascular smooth muscle cells.
29 
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CHAPTER 4 
MATERIALS AND METHODS 
 
Cell Culture 
A7r5 cells were cultured as described previously [61]. For overexpression 
studies, subcultured A7r5 cells at 50-70% confluence were transfected with a 
FLAG-tagged human KCNQ5 (or KCNQ4, or KCNQ4 and KCNQ5 in 
combination) DNA sequence, which was inserted into a pIRES-2-enhanced 
green fluorescent protein vector, using Lipofectamine (Invitrogen, Carlsbad, CA) 
transfection reagent according to the manufacturer’s protocol. Confluent 
subcultures of A7r5 cells were trypsinized with 0.25% trypsin +EDTA and 
replated on glass coverslips. Green fluorescent protein-expressing cells were 
used for electrophysiological recordings 5-10 days after transfection. 
 
Electrophysiology 
Whole cell perforated-patch configurations were used to measure 
membrane currents under voltage clamp conditions in single A7r5 cells. All 
experiments were performed at room temperature with continuous perfusion of 
external solution. It was not necessary to distinguish between endogenous and 
exogenous Kv7 currents in recordings where Kv7 channels were exogenously 
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expressed in A7r5 cells. Exogenous Kv7 current amplitude is approximately two 
orders of magnitude larger than the endogenously expressed Kv7.5 channel 
currents in the A7r5 cells; therefore, any contribution from endogenous current 
would be negligible [9].  
The external solution for measuring Kv7 K+ currents contained (in mM): 5 
KCl, 130 NaCl, 10 HEPES, 2 CaCl2, and 1.2 MgCl2. Bath solution pH was 
adjusted to 7.3 using NaOH. The bath solution osmolarity was adjusted to 269-
272 mOsm/L using D-glucose. The internal (pipette) solution contained (in mM): 
30 KCl, 110 K-gluconate, 5 HEPES, 1 K2EGTA. The internal solution pH was 
adjusted to 7.2 using KOH. The internal solution osmolarity was adjusted to 268-
272 mOsm/L using D-glucose.  
Recordings of native Kv7.5 currents in A7r5 cells required the addition of 
100 μM gadolinium (III) chloride (GdCl3) in the external solution to inhibit all non-
selective cation channels.  
Experiments in whole-cell perforated patch configuration were started with 
series resistance Rs < 30MΩ; cells with an abrupt decrease in Rs were discarded. 
Voltage-clamp command potentials were generated using an Axopatch 22B 
amplifier under the control of PCLAMP10 software. 
 
cAMP Assay 
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 The direct cAMP ELISA kit from Enzo Life Sciences (Cat#:ADI 900-066, 
Lot#:10071456D) was used. The kit is a competitive immunoassay for the 
quantitative determination of cyclic AMP in cells treated with hydrochloric acid 
(HCl). The optional acetylated assay format was used which provides a ~10-fold 
increase in sensitivity. Standards (cAMP standard; 2000 pmol/mL) and samples 
were added to wells of the provided 96-well plate per manufacturer instructions. 
Individual 35mm dishes of A7r5 cells were plated at 50-100,000 cells per mL and 
were serum deprived at 4pm the day before the assay was to be run. The 
experiment was run per the manufacturer’s protocol with the following 
modifications: Media was aspirated from each dish and washed with room 
temperature Kreb’s solution instead of PBS. Kreb’s solution contained (in mM): 
135 NaCl, 5.9 KCl, 1.5 CaCl2, 1.2 MgCl2, 11.6 HEPES, and 11.5 D-glucose. The 
solution pH was adjusted to 7.3 using NaOH. The protocol was lengthened to 
accommodate a resting period to minimize any mechanical stimulation washing 
may have caused, and cell scraping, sonication, and centrifugation steps were 
added to maximize the lysis of the cells and the amount of cAMP collected. The 
manufacturer provided 96-well plate was used for all samples and standards and 
the optical density was read in each well at 405nm on the Synergy HT plate 
reader located in our laboratory. The optical densities are read in each well after 
adjusting for the substrate blank, and the plate reader protocol calculates the 
concentration of cAMP according to a standard curve that is generated from the 
standards plated using a 4 parameter logistic (4PL) curve fitting program. The 
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amount of signal read at 405 nm is indirectly proportional to the amount of 
endogenous cAMP in the sample. Therefore, the more endogenous cAMP in the 
sample, the more conjugated cAMP will be outcompeted for binding with the 
antibody and the less yellow color will be produced when substrate is added.  
Statistics 
SigmaStat was used for all statistical analyses. Paired Student’s t-tests were 
used when comparing any parameters before and after treatment. Comparisons 
among multiple treatment groups were evaluated by analysis of variance 
(ANOVA) followed by a Holm-Sidak post hoc test. Differences where p ≤ 0.05 
were considered to be statistically significant. 
Materials 
AmpB, celecoxib, rolipram, forskolin, IBMX, and KT5720 were purchased 
from Tocris Research Laboratories (United Kingdom).
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CHAPTER 5 
RESULTS 
 
PDE Inhibition is Sufficient to Enhance Kv7 channel currents 
 Considering that celecoxib had been reported to be a PDE inhibitor [8] we 
first set about determining if this action could explain the observed effect of 
celecoxib on Kv7 currents. To determine if PDE inhibition is sufficient to enhance 
the currents through Kv7 channels, rolipram was used in electrophysiological 
studies. Bharath Mani, PhD, had previously found that rolipram, a PDE4 (cAMP 
specific) inhibitor mimicked celecoxib in its ability to enhance endogenous Kv7.5 
channel currents in A7r5 cells. (Not shown) He also found that rolipram mimicked 
celecoxib in its ability to inhibit L-type Ca2+ channels in A7r5 cells and promote 
vasodilation in vessels pre-constricted with the hormone arginine vasopressin 
(AVP) [85]. 
As stated previously in the literature review, A7r5 cells only express Kv7.5 
homo-tetramers while Kv7 channels in the vasculature can assemble as Kv7.4 
homotetramers, Kv7.5 homotetramers, and Kv7.4/7.5 heterotetramers. To 
determine if these channel assemblies are differentially regulated by the 
PDE/cAMP/PKA pathway, I used A7r5 cells overexpressing human (h)Kv7.4, 
hKv7.5, or both for electrophysiology experiments. Upon application of the PDE4 
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Figure 2: Rolipram enhances Kv7 currents in A7r5 cells expressing human Kv7 
channels. Current voltage relationship curves showing A7r5 cells expressing human 
Kv7 channels before (control, black circles) and after treatment with 100nM of the PDE4 
inhibitor, rolipram (white circles) (A) Mean IV curve of hKv7.4 currents showing no effect 
of rolipram; n=5 (B) Mean IV curve of hKv7.4/7.5 currents showing no effect of rolipram; 
n=5 (C) Mean IV curve of hKv7.5 currents showing enhancement upon treatment with 
rolipram; n=5 *Significant difference between control and 100nM rolipram treatments. 
Paired Student’s t-test; p<0.05, n=5 (CJ Robakowski, publication under review) 
 
 
 
 
 
35 
 
 
 
inhibitor, rolipram (100nM), hKv7.5 currents were enhanced but hKv7.4 and 
hKv7.4/7.5 currents were not affected. [Figure 2]  
 
Furthermore, treatment of A7r5 cells with the adenylyl cyclase activator, 
forskolin, in combination with the non-specific PDE inhibitor, IBMX, (10µM and 
500 µM respectively) also enhanced hKv7.5 currents. Once again, hKv7.4 
channel currents were unresponsive to regulation by this pathway even with the 
more robust combination of an adenylyl cyclase activator with a PDE inhibitor. 
However, the hetero-tetramer hKv7.4/7.5 did show a modest but significant 
enhancement with forskolin/IBMX treatment and became sensitive to regulation 
by the cAMP/PKA-dependent pathway with the more robust treatment 
combination. [Figure 3] While it is apparent that these channel assemblies are 
differentially sensitive to enhancement by PDE inhibition, it is unclear why one 
treatment would affect the hetero-tetrameric channel while the other would not. It 
is possible that the more robust forskolin/IBMX treatment used here produces a 
larger increase in the cellular concentration of cAMP than rolipram and this larger 
increase is required to elicit an effect on the less sensitive hKv7.4/7.5 channel 
currents. The question regarding the amount of cAMP produced by these 
different treatments is addressed later in the aim three experiments of this 
section. 
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Figure 3:  IBMX/Fsk treatment mimics celecoxib and rolipram in Kv7.5 
current enhancement. Current voltage curves of human Kv7 currents in A7r5 
cells before (control, black circles) and after treatment of 500 μM of non-specific 
PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX), and 10 μM of adenylyl cyclase 
activator, forskolin (Fsk), (white circles) (A) Mean IV curve of hKv7.4 currents 
showing no effect of IBMX/Fsk treatment. (B) Mean IV curve of hKv7.4/7.5 
currents showing little enhancement with IBMX/Fsk treatment. (C) Mean IV curve 
of hKv7.5 currents showing significant enhancement comparable to that seen 
with celecoxib and rolipram upon IBMX/Fsk treatment *Significant difference 
between control and IBMX/Fsk treatments. Paired Student’s t-test; p<0.05, n=4-
6. (CJ Robakowski and LI Brueggemann, publication under review) 
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While rolipram and the forskolin/IBMX combination were the only 
treatments I tested myself for this aim, other members of our laboratory have 
collected additional data to support the hypothesis that PDE inhibition and cAMP 
elevation are sufficient to enhance Kv7.5 channel currents. Bharath Mani 
previously found that another non-specific PDE inhibitor, papaverine, also dose-
dependently (10 µM and 100 µM) enhanced endogenous Kv7.5 currents in A7r5 
cells. [Figure 4] Dr. Lyubov Brueggemann found that increasing cAMP levels by 
addition of 1mM Br-cAMP, a membrane-permeant cAMP analogue, enhanced 
Kv7.5 channel currents in A7r5 cells. She also found that the adenylyl cyclase 
activator forskolin (1 µM) was sufficient by itself to enhance Kv7.5 channel 
currents.  [Figure 4] 
Altogether, these experiments suggest that PDE inhibition and cAMP 
elevation are sufficient to activate human Kv7.5 channels, as well as rat Kv7.5 
channels endogenously expressed in A7r5 cells, and this Kv7.5 channel 
activation mimics the celecoxib-induced activation observed previously. 
 
Celecoxib Requires a Critical Tryptophan Residue for Kv7.5 Channel 
Activation 
 There are clinically available Kv7 channel activators currently on the 
market. Retigabine is one such Kv7 channel activator and it is currently marketed 
as an anticonvulsant. Retigabine and many other pharmacological agents 
developed to activate Kv7 channels, share a common mechanism of action.  
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Figure 4. Elevation of cAMP enhances endogenous Kv7.5 currents in A7r5 cells. A. 
I-V relationships of endogenous Kv7.5 currents recorded in A7r5 cells before (control, 
filled circles), after 15 min treatment with 1 mM 8Br-cAMP (open circles) and after 10 
min of washout (filled triangles). Current were normalized to currents recorded at -20 mV 
before application of 8Br-cAMP (n= 4, * indicates significant difference from control, P < 
0.05, One Way Repeated Measures ANOVA). B. I-V relationships of endogenous Kv7.5 
currents recorded in A7r5 cells before (control, filled circles), after 5 min treatment with 1 
µM forskolin (open circles) and after 10 min of washout (filled triangles). Current were 
normalized to currents recorded at -20 mV before application of forskolin (n= 4, * 
indicates significant difference from control, P < 0.05, One Way Repeated Measures 
ANOVA). C. I-V relationships of endogenous Kv7.5 currents recorded in A7r5 cells 
before (control, filled circles), after 5 min treatment with 1 µM forskolin in the presence of 
500 µM IBMX (open circles) and after 10 min of washout (filled triangles). Current were 
normalized to currents recorded at -20 mV before application of forskolin/IBMX (n= 4, * 
indicates significant difference from control, P < 0.05, One Way Repeated Measures 
ANOVA). D. I-V relationships of endogenous Kv7.5 currents recorded in A7r5 cells 
before (control, filled circles) and after treatment with papaverine (10 µM open circles, 
100 µM open triangles). Current were normalized to currents recorded at -20 mV before 
application of papaverine (n= 4, * indicates significant difference from control, P < 0.01, 
One Way Repeated Measures ANOVA). (LI Brueggemann, publication under review) 
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These agents activate Kv7 channels by binding to a critical tryptophan residue 
located on the S5 pore-forming domain of the channel, thereby stabilizing its 
open conformation. This critical tryptophan residue is conserved in Kv7.2 – Kv7.5 
channels. On the Kv7.5 channel, the tryptophan is located at position 235.  
 When the tryptophan at residue 235 is mutated to a leucine (Q5W235L), 
the channel is rendered retigabine-insensitive, i.e., the channel is still functional 
but can no longer be regulated by retigabine or other typical pharmacological Kv7 
channel activators. Our laboratory possesses this Q5W235L mutant and I used it 
for the electrophysiology studies in aim 2.  
 First, rolipram was used as a positive control. Since it is known that 
rolipram is a PDE4 inhibitor and works through the indirect cAMP/PKA-
dependent pathway we are trying to study, it is expected to still be able to 
enhance the mutant Q5W235L channel currents. That is, in fact, what was 
observed. Application of rolipram (100nM) to the retigabine-insensitive mutant 
Kv7.5 channels resulted in enhancement of the currents as had been observed in 
A7r5 cells expressing the wild-type Q5 channels. [Figure 5] 
If celecoxib is also enhancing Kv7.5 currents through the indirect 
cAMP/PKA-dependent mechanism, then it too should enhance the currents 
through the Q5W235L mutant channels. However, the currents were not 
enhanced upon application of celecoxib (10µM). [Figure 6] There are two 
possible explanations for this result. First, it is possible that celecoxib enhances  
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Kv7.5 channel currents through the critical tryptophan residue as other 
pharmacological Kv7 activators do. It is also possible that celecoxib does not 
produce as much of an increase in cellular cAMP levels around the channel as 
rolipram does. In this case, the amount of cAMP produced in the cell after 
treatment with celecoxib may be insufficient to enhance the currents of the 
mutated, and therefore less sensitive, channel. This fundamental question is 
addressed by experiments in aim 3. 
 
Cellular concentrations of cAMP vary with different treatments 
Troubleshooting 
 The cAMP ELISA proved to be a learning process. There were several 
factors to consider and alter before finding a protocol that we felt produced the 
most accurate results for the question we sought to address. The original 
protocol, which was graciously taught to me by Dr. Abishek Tripathi in the 
Majetschak lab, required our A7r5 cells to be treated in suspension and included 
many spin and vortex steps. This was not ideal as A7r5 cells are normally 
adherent and are mechanically sensitive. This meant that those steps where the 
cells were detached and excessively handled could alter the cells’ signaling and 
response to treatments. Therefore, data collected in the initial run of the assay 
were disregarded. The protocol was then altered to reflect the way we handle the 
cells before biochemistry experiments such as western blots and 
immunoprecipitations. This prolonged the protocol by adding a 3 hour wait time 
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between washing the cells and treating them so as to minimize any mechanical 
stimulation before treatment. The cells were then lysed with the HCl provided in 
the kit and scraping, sonicating, and centrifugation steps were added to remove 
and lyse our adherent cells from their plates to collect the samples for the assay.  
When troubleshooting the high variability that I experienced when I first 
started running the assay, Dr. Patel brought up the excellent point HCl might not 
be sufficient to lyse our cells. After reading the troubleshooting literature available 
on Enzo Life Science’s website, I concluded that there are some cell lines that 
are hardier than others and require longer lysing times. To determine if the 10 
minute lysis time suggested in the protocol was sufficient, I used a plate of A7r5 
cells and washed it as I would in my normal assay protocol. I left the cells 
untreated, added the 0.1M HCl, and started a timer. I had the dish under a 
microscope so I could observe lysing of the cells and any other morphological 
changes in real time. This experiment revealed that the 10 minute lysis time 
suggested in the protocol was sufficient for our cell line. Additionally, the cell 
scraping, sonication, and centrifugation steps that we added to the protocol 
should have all but guaranteed that the cells were completely lysed and cellular 
contents were available for the assay. 
Another issue that presented itself when using this assay was that a 15-
minute treatment with isoproterenol, a beta-adrenergic agonist that was expected 
to stimulate adenylyl cyclase and produce cAMP to increase the cellular 
concentration of cAMP, did not yield cAMP concentrations above control. To 
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determine if the original treatment time (15 minutes) was not optimal, I ran a time 
course using the same concentration (1 µM) of isoproterenol for 30 seconds, 1 
minute, 2 minutes, 5 minutes, or 10 minutes. [Figure 7] A significant elevation of 
cAMP levels were observed, with the maximal levels of cAMP produced at the 1-
minute time point which then steadily declined at later time points. By the 10-
minunte time point, cAMP levels were back to baseline, presumably due, at least 
in part, to the activation of PDEs. The maximal 1-minute treatment time was used 
for the remainder of the experiments unless otherwise stated. 
 
Assay Results 
 To determine whether the different treatments used throughout this 
thesis work produce different amounts of cAMP to elicit the differential activation 
of the vascular Kv7 channels showed previously (hKv7.4, hKv7.5, and 
hKv7.4/7.5) the direct cAMP ELISA from Enzo Life Sciences was used. For this 
set of experiments, A7r5 cells were treated with vehicle, forskolin with IBMX, 
rolipram alone, celecoxib alone, or isoproterenol alone. As expected, the robust 
combination treatment of forskolin (adenylyl cyclase activator; 10 µM) and IBMX 
(non-specific PDE inhibitor; 500 µM) induced a significant increase in the cAMP 
concentration in A7r5 cells compared with cells treated with a DMSO vehicle 
control. [Figure 8] Both rolipram alone and celecoxib alone failed to produce a 
detectable change in cAMP levels compared to control. This is a reasonable  
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Figure 7: Isoproterenol Time Course. Each sample of A7r5 cells (run in 
duplicate) was treated with 1μM isoproterenol for various lengths of time. The 
peak concentration of cAMP upon isoproterenol treatment was reached at 1 
minute with the cellular levels of cAMP returning to baseline by the 10 minute 
time point. To elicit the maximal effect of isoproterenol in subsequent 
experiments, the 1 minute treatment time was used. n=1. (CJ Robakowski, 
unpublished) 
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result to obtain because there was no stimulatory step involved in those 
treatments. The only cAMP to be detected in those samples would have been the 
basal levels that were present in the cell at the time of treatment that were 
prevented from degradation. This is consistent with the results of Klein and 
colleagues, who reported that celecoxib only weakly increased cAMP levels in  
the assay they used; the increase they observed never reached statistical 
significance though their data was not shown [8]. In A7r5 cells, isoproterenol (1 
µM) alone induced a significant increase in cAMP levels compared to control. 
[Figure 8] This was expected, as isoproterenol is a beta-adrenergic agonist and 
should stimulate adenylyl cyclase activity to produce cAMP. Since neither 
celecoxib or rolipram alone produced a detectable change in cAMP levels, 
isoproterenol (1 µM) was administered simultaneously with either celecoxib or 
rolipram (10 µM or 100 nM respectively) with the rationale that stimulating cAMP 
production while inhibiting its degradation by PDE4 is likely to result in a higher 
overall concentration of cAMP than with isoproterenol alone. However, results 
were variable and even after repeating the experiment six times, isoproterenol in 
combination with either rolipram or celecoxib was not statistically different from 
isoproterenol alone. [Figure 9] It is possible that the short (1 minute), 
simultaneous treatment of the cells with isoproterenol along with celecoxib or 
rolipram did not provide sufficient time for celecoxib or rolipram to inhibit PDE4 
and cAMP degradation before the treatment was stopped and the cells were 
lysed.  To determine if the lack of change observed between the treatments was  
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Figure 8: cAMP is elevated to different concentrations with different 
treatments.  cAMP levels are very significantly and consistently increased upon 
combination treatment of forskolin with IBMX. PDE4 inhibitors, rolipram and 
celecoxib, do not significantly elevate cAMP concentrations alone. Isoproterenol 
(1μM) is able to significantly increase cAMP levels. *Significant difference by 
independent t-test compared to control; p<0.05, n=3-10. **Significant difference 
between control and Fsk/IBMX treatments; independent t-test, p<0.01, n=5-10. 
(CJ Robakowski, unpublished) 
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due to insufficient time, the assay was repeated and the treatment times were 
altered. Cells were treated with celecoxib or rolipram (10 µM or 100 nM 
respectively) five minutes prior to isoproterenol treatment. Isoproterenol (1 µM) 
was then added to the cells for 15 minutes. Previously, 15-minute isoproterenol 
treatments yielded cAMP levels that were comparable to baseline. [Figure 9] This 
is assumed to be due to the activation of PDEs. The rationale behind this new 
time course was that celecoxib and rolipram would have more time to elicit their 
inhibitory effects on PDE4 and prevent cAMP degradation before stimulation of 
cAMP production by an agonist occurred. Ideally, the addition of celecoxib or 
rolipram as a pretreatment would prevent the time-dependent degradation of 
cAMP observed with isoproterenol alone and would reveal differences in the 
effectiveness of celecoxib and rolipram to prevent cAMP degradation. The results 
of the celecoxib or rolipram pretreatment experiments were inconclusive. With 
only an n of 3 for both celecoxib and rolipram as pretreatments, the results were 
highly variable. Rolipram pretreatment before isoproterenol stimulation trended 
toward preventing the cAMP degradation that is observed between the 1- and 
15-minute time points with isoproterenol alone. [Figure 9] Celecoxib pretreatment 
before isoproterenol stimulation did not suggest a prevention of cAMP 
degradation based on its trend.   
 
 
 
48 
 
 
 
 
 
 
Figure 9: Celecoxib does not prevent cAMP degradation. cAMP levels return 
to baseline after treatment with 1μM isoproterenol  (ISO,15min) . Simultaneous 
treatment with a PDE4 inhibitor (rolipram, 100nM or celecoxib, 10μM) did not 
significantly increase cAMP levels with isoproterenol compared to isoproterenol 
alone. Only pretreatment with rolipram (100nM) prevented degradation of cAMP 
after isoproterenol treatment though it did not reach statistical significance. 
Celecoxib (10μM) treatment suggested an inability to prevent cAMP degradation 
when used as a pretreatment in cells later treated with isoproterenol. *Significant 
difference by independent t-test compared to control; p<0.05, n=3-10. 
#Significant difference between ISO alone at 1 minute and ISO alone at 15 
minutes; independent t-test, p<0.05, n=4-6. (CJ Robakowski, unpublished) 
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In summary, the results of this assay demonstrate that there is indeed a 
difference in the cellular concentrations of cAMP present after different 
treatments are administered. It is especially clear for the forskolin (10 µM) and 
IBMX (500 µM) combination treatment as it consistently produced a very 
significant (p<0.005) increase in cAMP concentration compared to the control. 
[Figure 8] These differences in the amount of cAMP generated with each 
treatment can provide a possible explanation as to why the forskolin/IBMX 
combination treatment enhanced the typically less sensitive hetero-tetrameric 
hKv7.4/7.5 channel currents while rolipram treatment did not. 
 
PKA activation is involved in celecoxib-induced Kv7 channel activation 
 In order to determine if PKA activation is involved in celecoxib-induced 
Kv7 channel activation, I utilized a PKA inhibitor, KT5720. This drug, when used 
as a pretreatment, should inhibit the activation of PKA [79] thus attenuating any 
downstream signaling, such as PKA-dependent channel activation. As a control, 
rolipram (100nM) was used. When cells were pretreated with KT5720 for 30 
minutes, the endogenous Kv7.5 channel current enhancement normally elicited 
by rolipram was completely attenuated compared to vehicle control. [Figure 10] 
 If celecoxib is activating endogenous Kv7.5 channel currents in a PKA-
dependent manner, then KT5720 pretreatment should also attenuate any 
celecoxib-induced enhancement of Kv7.5 currents. Interestingly, KT5720 
pretreatment (30minutes) did attenuate the celecoxib-induced enhancement of 
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Kv7.5 current relative to vehicle controls. [Figure 11] This suggests that celecoxib 
could, at least partially, require PKA activation to elicit its Kv7 channel activation. 
Further experiments will have to be completed to definitively implicate PKA 
activation in celecoxib-induced Kv7 channel enhancement and will be discussed 
in the future directions of this thesis. 
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CHAPTER 6 
DISCUSSION 
This thesis work sought to uncover the mechanism through which 
celecoxib enhances Kv7 currents, which was proposed to be the reason behind 
its safer cardiovascular risk profile. To determine if phosphodiesterase inhibition 
was the mechanism by which celecoxib elicits Kv7 channel activation, I sought to 
answer three main questions: 1.) Is PDE inhibition sufficient to enhance Kv7 
currents? 2.) Is PKA activation necessary for Kv7 current enhancement? 3.) 
Does celecoxib enhance Kv7 currents through a critical residue that is typical of 
other pharmacological Kv7 channel activators? 
 The data reported in chapter 5 suggest that PDE inhibition is in fact 
sufficient to enhance Kv7.5 channel currents. More importantly, the data revealed 
that different Kv7 channel subunit assemblies are differentially sensitive to 
regulation by the cAMP/PKA-dependent pathway being studied. This is important 
from a physiological standpoint because it provides insight into whether or not 
certain drugs would be efficacious in the vasculature. By using structurally 
different PDE inhibitors with different specificities for cAMP, I was able to mimic 
celecoxib’s ability to increase Kv7.5 currents as well as determine a treatment 
that was able to enhance the physiologically relevant and typically less sensitive 
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hKv7.4/7.5 hetero-tetrameric channel currents (10 µM forskolin/500 µM IBMX 
combination).  
 Utilizing the direct cAMP ELISA, I was able to gain insight into the 
differential regulation of different channel assemblies by the cAMP/PKA-
dependent pathway. The results from this assay revealed that there is a 
difference in the cellular concentration of cAMP following treatment of A7r5 cells. 
Forskolin and IBMX most significantly increased cAMP levels compared to 
control, and there was no detectable change in cAMP levels upon treatment with 
rolipram or celecoxib. This suggests that the larger increase in cAMP levels 
produced by the combination treatment of forskolin and IBMX could be 
responsible for the enhancement of the less sensitive heteromeric hKv7.4/7.5 
channel currents that is not mimicked with rolipram treatment.  
The ELISA data also brought to light the fact that celecoxib may be a 
weak PDE4 inhibitor at best. The hypothesis that celecoxib was a PDE4 inhibitor 
and was utilizing a cAMP/PKA-dependent pathway to activate Kv7 channels was 
developed after Klein et al reported celecoxib to increase both cGMP and cAMP 
levels in isolated rat aorta tissue. [8] However, Klein and colleagues never 
actually show the cAMP-specific data and simply state that celecoxib produced a 
weak, 1.6-fold increase in cAMP levels and that it did not reach statistical 
significance. [8] So while it was interesting to find the Kv7.4 and Kv7.5 channel 
subunits were differentially sensitive to regulation by a cAMP/PKA dependent 
pathway, it may not be the mechanism through which celecoxib is eliciting its Kv7 
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channel activation. It could turn out that celecoxib only activates the channel 
through its critical tryptophan residue just like retigabine and other Kv7 channel 
modulators.   
 Electrophysiology experiments that utilized the PKA inhibitor, KT5720, 
offered perspective on the involvement of the cAMP/PKA pathway on Kv7.5 
channel current enhancement. As expected, rolipram-induced Kv7.5 current 
enhancement was attenuated when cells were pretreated with KT5720, which 
inhibits activation of PKA. Interestingly, pretreatment of A7r5 cells with KT5720 
also prevented celecoxib-induced Kv7.5 current enhancement. This was 
interesting considering the data in which celecoxib was unable to enhance the 
mutant Kv7.5 channel currents suggested requirement of the critical tryptophan 
residue for celecoxib-induced enhancement of the channel. This was also 
interesting considering the preliminary cAMP ELISA data suggested celecoxib 
was unable to prevent the degradation of cAMP produced after isoproterenol 
treatment and did not show any detectable elevation in cAMP levels when used 
as a treatment on its own. There have been reports that PKA inhibitors KT5720 
and H89 have many non-specific targets that effect many different signaling 
pathways and are not a reliable indication of PKA involvement on their own [80]. 
A more accurate way to implicate PKA involvement in a specific signaling event, 
as we are attempting to do, would require the combination use of KT5720 with a 
protein kinase inhibitor peptide or a more specific molecular method such as 
RNA interference (RNAi) [81]. Directly measuring PKA activity in response to 
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celecoxib treatment would also better implicate the necessity of PKA activation 
for celecoxib-induced current enhancement. This further validates the need for 
future exploration into the exact mechanism of celecoxib.  
While I originally sought to determine whether or not PDE inhibition/cAMP 
elevation is necessary for celecoxib-induced Kv7 channel activation, with the 
data discussed above, I cannot draw that conclusion. This is due to the fact that 
PKA activation, the assumed downstream effect of PDE inhibition/cAMP 
elevation, was only shown to be potentially involved in celecoxib-induced Kv7 
channel activation and in fact, data from the mutant channel experiments lends 
more evidence to celecoxib requiring the critical tryptophan residue to elicit its 
effect. Additionally, the cAMP ELISA data was inconclusive as to whether or not 
celecoxib elevated cAMP levels either on its own or in combination with a 
stimulus such as isoproterenol. Given the inconclusive nature of the data 
discussed, further work must be completed before PDE inhibition/cAMP 
elevation’s necessity in celecoxib-induced Kv7 channel activation can be 
concluded. As it stands, the data suggest multiple possible mechanisms by which 
celecoxib could be eliciting its Kv7 channel activation with better evidence 
suggesting requirement of the critical residue for channel activation than an 
indirect PDE4/cAMP/PKA-dependent pathway.    
 Protein kinase A anchoring proteins add another layer of complexity to 
celecoxib’s mechanism of Kv7 channel modulation. It is worth noting that PKA 
anchoring proteins offer cAMP signaling specificity by placing PKA in proximity to 
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specific substrates and effectors [82]. AKAP 79/150, in particular, has been 
reported to be an important component of PKA and PKC-mediated 
phosphorylation of other ion channels [83]. AKAPs position PKA in close spatial 
proximity to specific substrates that allow a localized increase in cAMP to confine 
PKA phosphorylation to that specific subset of substrates. It is still unknown, 
however, if localized or global increases in cAMP are responsible for the cAMP-
dependent enhancement of Kv7.5 currents that we have observed in this study, 
and we have yet to explore any role of AKAP in our present findings. It could be 
worth exploring this role as detailed in the future directions portion of this thesis. 
 Recently, the Greenwood lab published an article reporting Kv7.4 channel 
activation by the heterotrimeric G-protein βγ subunits [84]. In that report, 
Greenwood and colleagues reported that β-AR-Gβγ subunit signaling activates 
Kv7.4 channels in HEK cells heterologously expressing Kv7.4 and in rat renal 
artery myocytes. They reported that G-protein βγ subunits enhanced the open 
probability of Kv7.4 channels and gallein, an inhibitor of Gβγ subunits, prevented 
stimulatory effects. Only Kv7.4 channel activity was explored, however [84]. And 
as stated previously, Kv7.4 and Kv7.5 predominantly form heterotetramers in the 
vasculature. Since effects on Kv7.5 and Kv7.4/7.5 channels activities were not 
explored in that report, it is unclear whether β-AR-Gβγ subunit signaling is 
relevant physiologically. Results from our laboratory (Mani et al., manuscript 
submitted) do not reproduce the enhancement of Kv7.4 currents by isoproterenol 
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reported by Stott et al., though our results are based on expression of Kv7.4 in 
A7r5 cells rather than HEK cells. However, it’s possible that the β-AR activation 
could mediate vasodilatory responses by activating different Kv7 channel 
subunits through diverse signaling molecules. 
 Lastly, it is unclear what, if any, structural differences between celecoxib 
and rofecoxib are responsible for the difference in their ability to activate Kv7 
channels. The sulfone group of rofecoxib (which is a sulfonamide in celecoxib) is 
what allows rofecoxib to be more specific for COX-2 than celecoxib [2]. But since 
we concluded that the Kv7 channel activation by celecoxib is independent of its 
COX-2 inhibitory activity, it is unclear of those different groups play a role in Kv7 
channel activation. There are a few other noteworthy difference between 
rofecoxib and celecoxib. Rofecoxib contains a furanone heterocycle and contains 
no fluorine or additional groups on its aromatic ring [2]. Celecoxib contains a 
pyrazole heterocycle with a tri-fluorinated carbon as well as a methyl group on its 
aromatic ring [2]. Any of these structural differences could be responsible for the 
difference in celecoxib and rofecoxib’s abilities to activate the Kv7 channels but 
that has not yet been explored. 
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CHAPTER 7 
FUTURE DIRECTIONS 
PKA Phosphorylation Studies 
 From the data collected, it is clear that at least the Kv7.5 subunits are 
sensitive to a cAMP/PKA-dependent pathway. First, it would be beneficial to 
determine if treatment with celecoxib affects PKA activation. This could be done 
using cell lysates with fluorescence based assays like those detailed by Shults 
and colleagues in Nature Methods [86]. Normally when PKA is activated, it goes 
on to phosphorylate and activate many downstream effectors. It would also be 
helpful to investigate whether or not there is a phosphorylation of the Kv7.5 
channel associated with its activation by PKA. Using MIT scansite software, 11 
putative PKA phosphorylation sites exist within the Kv7.5 amino acid sequence. 
These sites exist both on the N-terminus and C-terminus of the channel. Our 
laboratory has attempted to create mutant channels with either the C or N-
terminus truncated to determine which residues are important for PKA regulation, 
but those mutants never resulted in functional channels. A strategy that could be 
employed to answer the question as to which, if any, residue(s) is necessary for 
PKA regulation would be to construct point mutations of candidate 
phosphorylation sites to render the protein unphosphorylatable at these sites. 
Each potential residue could be point mutated and electrophysiology experiments 
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could be run to determine the functional necessity of each of the potential PKA 
residues. Once this residue is determined, further studies can be done to assess 
whether that phosphorylation site can be exploited therapeutically. This is also 
important information to have because we reported that different Kv7 subunits 
are differentially regulated by this PKA pathway and some, like Kv7.4, are 
seemingly insensitive to PKA regulation. Using the same MIT scansite software, 
only three putative PKA phosphorylation sites were identified in the Kv7.4 
sequence. Of those three sites, only two corresponded to analogous amino acid 
sequences in the Kv7.5 channel. The fact that there are so many more potential 
PKA phosphorylation sites on the Kv7.5 channel and so few on the Kv7.4 
channel could explain the differences in sensitivity to PKA regulation between the 
two subunits. 
Revisit cGMP Pathway 
 The Klein paper that reported celecoxib to be a PDE inhibitor reported that 
celecoxib, and not rofecoxib, was both a PDE4 (cAMP-specific 
phosphodiesterase) and a PDE5 (cGMP-specific phosphodiesterase) inhibitor 
and their evidence for PDE5 inhibition was much stronger than for PDE4 
inhibition [8]. Inhibition of PDE5 would result in higher levels of cGMP and the 
cGMP-NO pathway is a well-defined vasodilatory pathway so it may be worth 
revisiting. Electrophysiology experiments could be repeated with a PDE5 
inhibitor, such as tadalafil or sildenafil, to see if they, too, mimic celecoxib’s ion 
channel modulatory activity. There is also a chance that there is significant cross-
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talk between the cAMP and cGMP pathways that could further complicate the 
mechanism of Kv7 channel current enhancement that we report here. If it turns 
out that PDE5 inhibition mimics the Kv7.5 current enhancement seen with PDE4 
inhibitors, there also exist PKG inhibitors that could be used as a pretreatment in 
the A7r5 cells similar to the experiment I showed previously using PKA inhibitor, 
KT5720. The PKG inhibitor, KT5823, works in much the same way and would 
attenuate any cGMP-induced Kv7 current enhancement when used as a 
pretreatment in the cells. Electrophysiology experiments utilizing KT5823 would 
give insight into the necessity of the cGMP pathway in celecoxib’s Kv7 channel 
activation. It would also be interesting to replicate Klein et al.’s reported 
celecoxib-induced increase in cGMP levels using an ELISA kit akin to the direct 
cAMP ELISA kit used in this thesis work. Klein et al stated that PDE5 inhibition 
was more important than PDE4 inhibition to the vasodilatory effect exhibited by 
celecoxib in their experiments and it would be interesting to see if the same trend 
was present in our hands. 
DMC as a PDE inhibitor 
 Our laboratory previously reported that celecoxib’s ion channel modulatory 
activity was independent of its COX-2 inhibitory activity. This conclusion was 
drawn after dimethyl celecoxib (DMC) a structural analogue of celecoxib that 
lacks any COX-2 inhibitory activity, was able to mimic celecoxib in its ability to 
enhance Kv7 channel currents as well as inhibit L-type calcium channel currents. 
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Furthermore, rofecoxib, which has an even higher affinity for COX-2 than 
celecoxib, was unable to mimic either of these ion channel modulatory effects.  
 It would be interesting to explore whether DMC also mimicked celecoxib’s 
ability to inhibit PDE4 or PDE5. Literature searches yielded no studies in which 
this specific effect was studied for DMC. If it turns out that DMC also inhibits 
PDE4 and/or PDE5 activity, it could lead to insight regarding celecoxib’s 
mechanism of Kv7 current enhancement. For instance, if DMC is found to be a 
PDE4 inhibitor but not a PDE5 inhibitor, it could lend more support to the 
cAMP/PKA mechanism for Kv7 channel regulation. If DMC is a PDE5 inhibitor as 
well, it would support the need to revisit the cGMP pathway and its potential 
effect on the Kv7 enhancement we have observed previously. 
AKAP 
As discussed in the previous chapter, anchoring proteins are important for 
bringing signaling components in close proximity to the substrates they target. 
AKAPs allow for PKA signaling to be determined by the specific pools of cAMP 
within their vicinity, thus distinguishing between different pools of cAMP within 
the cell. AKAPs have been reported to bring PKA, PDEs, and substrates such as 
ion channels together to promote targeted signaling. It has yet to be determined if 
any anchoring proteins play a role in celecoxib’s mechanism of Kv7 channel 
activation. It would be worth exploring if there exists a signaling complex that 
brought together the Kv7 channels of interest with PKA and PDE4. To explore 
this, experiments would have to be run to determine if any of those signaling 
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components are in close proximity which could provide insight into the possibility 
of a signaling complex being involved in celecoxib’s mechanism of Kv7 channel 
activation. Our laboratory found previously that AKAP150 co-immunoprecipitates 
with the Kv7.5 channel in A7r5 cells [unpublished]. It has yet to be explored 
whether PDE4 or PDE5 are also present in those immunoprecipitates. Proximity 
ligation assays might be a better method for exploring our direct protein-protein 
interactions of interest. 
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